Consent forms should explicitly outline the risks, benefits, and the specific nature of the compounded drug being administered
Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, et al
In SURMOUNT-1, adults with obesity (without diabetes) lost an average of 15.0%, 19.5%, and 20.9% of body weight with tirzepatide 5 mg, 10 mg, and 15 mg respectively over 72 weeks, compared to 3.1% with placebo
AOD 9604 is a synthetic fragment of human growth hormone, specifically amino acids 176 through 191 of the hGH sequence, with a single modification at the N-terminus for stability
Finally, we discuss the implications of evolving policies (such as NICEs threshold increases and U.S